{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:00:13Z","timestamp":1792083613943,"version":"4.4.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001729","name":"Stiftelsen f\u00f6r Strategisk Forskning","doi-asserted-by":"publisher","award":["SB16-0058"],"award-info":[{"award-number":["SB16-0058"]}],"id":[{"id":"10.13039\/501100001729","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2017-06095"],"award-info":[{"award-number":["2017-06095"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","award":["2015.0291"],"award-info":[{"award-number":["2015.0291"]}],"id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006313","name":"Barncancerfonden","doi-asserted-by":"publisher","award":["TJ2021-0080"],"award-info":[{"award-number":["TJ2021-0080"]}],"id":[{"id":"10.13039\/501100006313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","award":["2024-00304"],"award-info":[{"award-number":["2024-00304"]}],"id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    FLT3-mutated acute myeloid leukemia (AML) remains difficult to treat due to frequent resistance to FLT3 inhibitors like midostaurin. In this study, we observed a progenitor-like CD38\n                    <jats:sup>+<\/jats:sup>\n                    CD45RA\n                    <jats:sup>+<\/jats:sup>\n                    leukemic cell population that may be associated with midostaurin resistance. Midostaurin-resistant cells display disrupted membrane architecture and a shift in signaling from STAT5 to PI3K\/AKT, favoring survival over apoptosis. Functional drug testing was consistent with clinical response to midostaurin, and together with multi-omic profiling, including single-cell and proteomic analyses, indicated the presence and relevance of this resistant phenotype. Drug combination screening revealed that co-targeting with SMAC mimetics restores apoptotic competence and selectively depletes the resistant population when combined with midostaurin. In contrast, venetoclax combinations preferentially affected CD34\n                    <jats:sup>hi<\/jats:sup>\n                    cells, underscoring distinct subpopulation vulnerabilities. These findings may point to a biologically relevant mechanism underlying midostaurin resistance.\n                  <\/jats:p>","DOI":"10.1038\/s41698-026-01363-8","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:47:33Z","timestamp":1773233253000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Midostaurin response in AML is shaped by a progenitor-like cell state selectively targeted by SMAC mimetics"],"prefix":"10.1038","volume":"10","author":[{"given":"Nona","family":"Struyf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Gezelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Lundmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Barizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidde","family":"Ploeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Rico Pizarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Vesterlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Mermelekas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albin","family":"\u00d6sterroos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bohlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Bengtz\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Hamberg Levedahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozbeh","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas M.","family":"Orre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Lehti\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4ivi","family":"\u00d6stling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brinton","family":"Seashore-Ludlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Nordlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6ren","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli","family":"Kallioniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Erkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"1363_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner, H., Weisdorf, D. J. & Bloomfield, C. D. Acute myeloid leukemia. N. Engl. J. Med. 373, 1136\u20131152 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1363_CR2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver, N., Schlenk, R. F., Russell, N. H. & Levis, M. J. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia 33, 299\u2013312 (2019).","journal-title":"Leukemia"},{"key":"1363_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner, H. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140, 1345\u20131377 (2022).","journal-title":"Blood"},{"key":"1363_CR4","doi-asserted-by":"publisher","first-page":"100905","DOI":"10.1016\/j.blre.2021.100905","volume":"52","author":"JC Zhao","year":"2022","unstructured":"Zhao, J. C. et al. A review of FLT3 inhibitors in acute myeloid leukemia. Blood Rev. 52, 100905 (2022).","journal-title":"Blood Rev."},{"key":"1363_CR5","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone, R. M. et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N. Engl. J. Med. 377, 454\u2013464 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1363_CR6","unstructured":"Samverkan, R. C. I. Antitumoral regim-Akut myeloisk leukemi (AML)\u2014Cytarabin-Daunorubicin 5+3 d\u2009+\u2009Midostaurin (DA 3+5\u2009+\u2009Midostaurin). https:\/\/kunskapsbanken.cancercentrum.se\/lakemedelsregimer\/akut-myeloisk-leukemi-aml\/cytarabin-daunorubicin-53-d--midostaurin\/ (2024)."},{"key":"1363_CR7","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba, H. P. et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401, 1571\u20131583 (2023).","journal-title":"Lancet"},{"key":"1363_CR8","unstructured":"M. R. A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination with Induction and Consolidation Therapy Followed by One-year Maintenance in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes with Excess Blasts-2 (MDS-EB2) with FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML\/AMLSG 28-18) https:\/\/clinicaltrials.gov\/study\/NCT04027309 (2024)."},{"key":"1363_CR9","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","volume":"106","author":"R Singh Mali","year":"2021","unstructured":"Singh Mali, R. et al. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models. Haematologica 106, 1034\u20131046 (2021).","journal-title":"Haematologica"},{"key":"1363_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00670-0","volume":"12","author":"M Yilmaz","year":"2022","unstructured":"Yilmaz, M. et al. Hypomethylating agent and venetoclax with FLT3 inhibitor \u201ctriplet\u201d therapy in older\/unfit patients with FLT3 mutated AML. Blood Cancer J. 12, 77 (2022).","journal-title":"Blood Cancer J."},{"key":"1363_CR11","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1158\/1535-7163.MCT-06-0810","volume":"6","author":"E Weisberg","year":"2007","unstructured":"Weisberg, E. et al. Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Mol. Cancer Ther. 6, 1951\u20131961 (2007).","journal-title":"Mol. Cancer Ther."},{"key":"1363_CR12","doi-asserted-by":"publisher","unstructured":"Ara\u00fajo, J. L. et al. FLT3 is genetically essential for ITD-mutated leukemic stem cells but dispensable for human hematopoietic stem cells. Blood. 2025; https:\/\/doi.org\/10.1182\/blood.2024025886.","DOI":"10.1182\/blood.2024025886"},{"key":"1363_CR13","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","volume":"3","author":"T Pemovska","year":"2013","unstructured":"Pemovska, T. et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 3, 1416\u20131429 (2013).","journal-title":"Cancer Discov."},{"key":"1363_CR14","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129, 424\u2013447 (2017).","journal-title":"Blood"},{"key":"1363_CR15","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P van Galen","year":"2019","unstructured":"van Galen, P. et al. Single-cell RNA-Seq reveals AML hierarchies relevant to disease progression and immunity. Cell 176, 1265\u20131281 e24 (2019).","journal-title":"Cell"},{"key":"1363_CR16","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","volume":"28","author":"AGX Zeng","year":"2022","unstructured":"Zeng, A. G. X. et al. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nat. Med. 28, 1212\u20131223 (2022).","journal-title":"Nat. Med."},{"key":"1363_CR17","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"1363_CR18","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/s41592-024-02268-9","volume":"21","author":"F Karlsson","year":"2024","unstructured":"Karlsson, F. et al. Molecular pixelation: spatial proteomics of single cells by sequencing. Nat. Methods 21, 1044\u20131052 (2024).","journal-title":"Nat. Methods"},{"key":"1363_CR19","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1158\/2159-8290.CD-21-0538","volume":"12","author":"C Kornauth","year":"2022","unstructured":"Kornauth, C. et al. Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders. Cancer Discov. 12, 372\u2013387 (2022).","journal-title":"Cancer Discov."},{"key":"1363_CR20","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.3324\/haematol.2022.281692","volume":"108","author":"H Kuusanm\u00e4ki","year":"2023","unstructured":"Kuusanm\u00e4ki, H. et al. Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia. Haematologica 108, 1768\u20131781 (2023).","journal-title":"Haematologica"},{"key":"1363_CR21","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","volume":"12","author":"D Malani","year":"2022","unstructured":"Malani, D. et al. Implementing a functional precision medicine tumor board for acute myeloid leukemia. Cancer Discov. 12, 388\u2013401 (2022).","journal-title":"Cancer Discov."},{"key":"1363_CR22","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1182\/blood-2016-02-699363","volume":"130","author":"R Karjalainen","year":"2017","unstructured":"Karjalainen, R. et al. JAK1\/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. Blood 130, 789\u2013802 (2017).","journal-title":"Blood"},{"key":"1363_CR23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2022.280800","volume":"108","author":"P Stelmach","year":"2023","unstructured":"Stelmach, P. & Trumpp, A. Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica 108, 353\u2013366 (2023).","journal-title":"Haematologica"},{"key":"1363_CR24","doi-asserted-by":"publisher","first-page":"5402","DOI":"10.1182\/bloodadvances.2020001802","volume":"4","author":"JM Ho","year":"2020","unstructured":"Ho, J. M. et al. CD200 expression marks leukemia stem cells in human AML. Blood Adv. 4, 5402\u20135413 (2020).","journal-title":"Blood Adv."},{"key":"1363_CR25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/bjh.13941","volume":"173","author":"B Kersten","year":"2016","unstructured":"Kersten, B. et al. CD45RA, a specific marker for leukaemia stem cell sub-populations in acute myeloid leukaemia. Br. J. Haematol. 173, 219\u2013235 (2016).","journal-title":"Br. J. Haematol."},{"key":"1363_CR26","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ccell.2015.03.009","volume":"27","author":"AH Shih","year":"2015","unstructured":"Shih, A. H. et al. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell 27, 502\u2013515 (2015).","journal-title":"Cancer Cell"},{"key":"1363_CR27","doi-asserted-by":"publisher","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","volume":"25","author":"J Ma","year":"2019","unstructured":"Ma, J. et al. Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia. Clin. Cancer Res. 25, 6815\u20136826 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1363_CR28","doi-asserted-by":"publisher","first-page":"49420","DOI":"10.1074\/jbc.M407700200","volume":"279","author":"P Hu","year":"2004","unstructured":"Hu, P., Han, Z., Couvillon, A. D. & Exton, J. H. Critical role of endogenous Akt\/IAPs and MEK1\/ERK pathways in counteracting endoplasmic reticulum stress-induced cell death. J. Biol. Chem. 279, 49420\u201349429 (2004).","journal-title":"J. Biol. Chem."},{"key":"1363_CR29","doi-asserted-by":"publisher","first-page":"eabb4324","DOI":"10.1126\/scisignal.abb4324","volume":"14","author":"M van der Vlist","year":"2021","unstructured":"van der Vlist, M. et al. Signaling by the inhibitory receptor CD200R is rewired by type I interferon. Sci. Signal. 14, eabb4324 (2021).","journal-title":"Sci. Signal."},{"key":"1363_CR30","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s40425-019-0710-1","volume":"7","author":"D Mahadevan","year":"2019","unstructured":"Mahadevan, D. et al. Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200. J. Immunother. Cancer 7, 227 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1363_CR31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/35053086","volume":"409","author":"J Irie-Sasaki","year":"2001","unstructured":"Irie-Sasaki, J. et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature 409, 349\u2013354 (2001).","journal-title":"Nature"},{"key":"1363_CR32","doi-asserted-by":"publisher","first-page":"E9338","DOI":"10.1073\/pnas.1710358114","volume":"114","author":"CB Carbone","year":"2017","unstructured":"Carbone, C. B. et al. In vitro reconstitution of T cell receptor-mediated segregation of the CD45 phosphatase. Proc. Natl. Acad. Sci. USA 114, E9338\u2013e9345 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1363_CR33","doi-asserted-by":"publisher","first-page":"598","DOI":"10.3389\/fcell.2020.00598","volume":"8","author":"VD Balise","year":"2020","unstructured":"Balise, V. D., Saito-Reis, C. A. & Gillette, J. M. Tetraspanin scaffold proteins function as key regulators of hematopoietic stem cells. Front. Cell Dev. Biol. 8, 598 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"1363_CR34","doi-asserted-by":"publisher","first-page":"111006","DOI":"10.1016\/j.celrep.2022.111006","volume":"39","author":"VE Dunlock","year":"2022","unstructured":"Dunlock, V. E. et al. Tetraspanin CD53 controls T cell immunity through regulation of CD45RO stability, mobility, and function. Cell Rep. 39, 111006 (2022).","journal-title":"Cell Rep."},{"key":"1363_CR35","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1038\/s41388-020-1261-0","volume":"39","author":"M Floren","year":"2020","unstructured":"Floren, M. et al. Tetraspanin CD82 drives acute myeloid leukemia chemoresistance by modulating protein kinase C alpha and \u03b21 integrin activation. Oncogene 39, 3910\u20133925 (2020).","journal-title":"Oncogene"},{"key":"1363_CR36","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1158\/0008-5472.CAN-11-2428","volume":"72","author":"L Bai","year":"2012","unstructured":"Bai, L. et al. LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNF\u03b1 expression and receptor tyrosine kinase signaling. Cancer Res. 72, 1229\u20131238 (2012).","journal-title":"Cancer Res."},{"key":"1363_CR37","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1172\/JCI34120","volume":"118","author":"DS Ziegler","year":"2008","unstructured":"Ziegler, D. S. et al. Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. J. Clin. Investig. 118, 3109\u20133122 (2008).","journal-title":"J. Clin. Investig."},{"key":"1363_CR38","doi-asserted-by":"publisher","unstructured":"Lin, A. et al. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci. Transl. Med. 11, https:\/\/doi.org\/10.1126\/scitranslmed.aaw8412 (2019)","DOI":"10.1126\/scitranslmed.aaw8412"},{"key":"1363_CR39","doi-asserted-by":"publisher","first-page":"TPS6580","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS6580","volume":"43","author":"P Montesinos","year":"2025","unstructured":"Montesinos, P. et al. QuANTUM-Wild: a phase 3, randomized, double-blind, placebo-controlled trial of quizartinib in combination with chemotherapy and as single-agent maintenance in FLT3-ITD\u2013negative acute myeloid leukemia (AML). J. Clin. Oncol. 43, TPS6580\u2013TPS6580 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1363_CR40","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ymeth.2013.04.006","volume":"61","author":"J Ryan","year":"2013","unstructured":"Ryan, J. & Letai, A. BH3 profiling in whole cells by fluorimeter or FACS. Methods 61, 156\u2013164 (2013).","journal-title":"Methods"},{"key":"1363_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00528-7","volume":"8","author":"N Struyf","year":"2024","unstructured":"Struyf, N. et al. Delineating functional and molecular impact of ex vivo sample handling in precision medicine. NPJ Precis. Oncol. 8, 38 (2024).","journal-title":"NPJ Precis. Oncol."},{"key":"1363_CR42","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1021\/acs.jproteome.7b00913","volume":"17","author":"S Moggridge","year":"2018","unstructured":"Moggridge, S., Sorensen, P. H., Morin, G. B. & Hughes, C. S. Extending the compatibility of the SP3 paramagnetic bead processing approach for proteomics. J. Proteome Res. 17, 1730\u20131740 (2018).","journal-title":"J. Proteome Res."},{"key":"1363_CR43","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nmeth.2732","volume":"11","author":"RM Branca","year":"2014","unstructured":"Branca, R. M. et al. HiRIEF LC\u2013MS enables deep proteome coverage and unbiased proteogenomics. Nat. Methods 11, 59\u201362 (2014).","journal-title":"Nat. Methods"},{"key":"1363_CR44","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nbt.3134","volume":"33","author":"J Boekel","year":"2015","unstructured":"Boekel, J. et al. Multi-omic data analysis using Galaxy. Nat. Biotechnol. 33, 137\u2013139 (2015).","journal-title":"Nat. Biotechnol."},{"key":"1363_CR45","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1038\/leu.2017.48","volume":"31","author":"M Wang","year":"2017","unstructured":"Wang, M. et al. Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling. Leukemia 31, 2029\u20132036 (2017).","journal-title":"Leukemia"},{"key":"1363_CR46","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1093\/bioinformatics\/btaa138","volume":"36","author":"S Potdar","year":"2020","unstructured":"Potdar, S. et al. Breeze: an integrated quality control and data analysis application for high-throughput drug screening. Bioinformatics 36, 3602\u20133604 (2020).","journal-title":"Bioinformatics"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01363-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01363-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01363-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:07:40Z","timestamp":1773770860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01363-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1363"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01363-8","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"117"}}